Status:

COMPLETED

A Community-based Assessment of Skin Care, Allergies, and Eczema

Lead Sponsor:

Oregon Health and Science University

Collaborating Sponsors:

University of Wisconsin, Madison

University of Colorado, Denver

Conditions:

Atopic Dermatitis

Atopic Disorders

Eligibility:

All Genders

1-63 years

Phase:

NA

Brief Summary

Atopic dermatitis (AD) affects over 9 million children in the U.S. and often heralds the development of asthma, food allergy, skin infections and neurodevelopmental disorders. Recent advances identify...

Detailed Description

AD affects over 9 million children in the U.S. and ranks first among all skin conditions in global disability burden. AD often heralds the development of several comorbidities including asthma, food a...

Eligibility Criteria

Inclusion

  • Parent can provide electronic signed and dated informed consent form.
  • Parent is willing and able to comply with all study procedures for the duration of the study.
  • Parent is a primary caretaker of an infant 0 to 2 months of age.
  • Parent is 18 years of age or older at time of consent.
  • Parent can speak, read, and write in English or Spanish.
  • Parent has a valid e-mail address or phone that can receive text messages
  • Parent has reliable access to the internet.
  • Infant is a patient of a participating Meta-LARC clinic site at the time of consent.

Exclusion

  • Infant was born at less than 25 weeks gestational age.
  • Infant has established eczema as diagnosed by the primary healthcare provider at clinic site of enrollment per parent report.
  • Infant has known adverse reaction to petrolatum-based emollients.
  • Infant has an immunodeficiency genetic syndrome such as Wiskott-Aldrich Syndrome or Severe Combined Immunodeficiency Syndrome.
  • Infant has extremely low birth weight (less than 1000g or 2.2 lbs at birth).
  • Infant has a sibling enrolled in the study.
  • Parent is unwilling or unable to comply with study procedures.

Key Trial Info

Start Date :

July 16 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 31 2024

Estimated Enrollment :

1260 Patients enrolled

Trial Details

Trial ID

NCT03409367

Start Date

July 16 2018

End Date

January 31 2024

Last Update

August 15 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

University of Colorado-Denver

Denver, Colorado, United States, 80045

2

Duke University

Durham, North Carolina, United States, 27705

3

Oregon Health & Science University

Portland, Oregon, United States, 97239

4

University of Wisconsin-Madison

Madison, Wisconsin, United States, 53175